Digital strategies in manufacturing and supply chain

Leonard Lerer and Mike Piper

Chapter Chapter 6 in Digital Strategies in the Pharmaceutical Industry, 2003, pp 79-87 from Palgrave Macmillan

Abstract: Abstract As biomedical products must have an excellent safety profile, the pharmaceutical manufacturing and supply chain is highly regulated, but is otherwise similar to those of many other industries. Companies purchase raw materials for bulk synthesis of active and inactive ingredients, thereafter drugs are formulated and packaged into various delivery mechanisms (solutions for injection, inhalers and pills of various types). Despite this similarity with other industries, there is substantial potential to improve the pharmaceutical supply chain and increase asset utilization (Table 6.1).

Keywords: Supply Chain; Supply Chain Management; Good Manufacturing Practice; Supply Chain Partner; Pharmaceutical Manufacturing (search for similar items in EconPapers)
Date: 2003
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-59879-9_6

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230598799

DOI: 10.1057/9780230598799_6

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().